Possible Biomarkers for Cancer Immunotherapy.
cancer immunotherapy
gut microbiome
mismatch repair status
neoantigens
programmed cell death-ligand 1 expression
specific gene mutations
tumor mutational burden
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
03 Jul 2019
03 Jul 2019
Historique:
received:
24
05
2019
revised:
18
06
2019
accepted:
30
06
2019
entrez:
7
7
2019
pubmed:
7
7
2019
medline:
7
7
2019
Statut:
epublish
Résumé
Immune checkpoint inhibitors (ICIs) have drastically changed the clinical care of cancer. Although cancer immunotherapy has shown promise in various types of malignancies, thus far, the proportion of patients who can benefit from ICIs is relatively small. Immune-related adverse events and high cost are unavoidable problems. Therefore, biomarkers defining patients that are most likely to benefit from ICIs are urgently needed. The expression of programmed cell death-ligand 1 (PD-L1) is a logical biomarker for the prediction of response to anti-PD1/PD-L1 immunotherapies. However, its usefulness is currently debatable because of its varied definition, threshold, and spatial/temporal heterogeneity. Recently, it was reported that the tumor mutational burden, expression of neoantigens, mismatch repair status, and specific gene mutations may be markers for the success of treatment with ICIs. Moreover, it was suggested that the fecal microbiota prior to immunotherapy may play an important role in predicting the efficacy of ICIs. In this review, we focused on these potential biomarkers for cancer immunotherapy reported in recent clinical articles. Further studies are warranted to develop a predictive model using these biomarkers, with the aim of practicing precision medicine in cancer immunotherapy.
Identifiants
pubmed: 31277279
pii: cancers11070935
doi: 10.3390/cancers11070935
pmc: PMC6678720
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Fam Cancer. 2009;8(3):231-9
pubmed: 19165625
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Cancer Discov. 2015 Jan;5(1):43-51
pubmed: 25358689
N Engl J Med. 2014 Dec 4;371(23):2189-2199
pubmed: 25409260
Nature. 2014 Nov 27;515(7528):563-7
pubmed: 25428504
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
J Clin Oncol. 2015 May 1;33(13):1430-7
pubmed: 25452452
J Clin Oncol. 2015 Jun 10;33(17):1889-94
pubmed: 25667295
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Science. 2015 Apr 3;348(6230):69-74
pubmed: 25838375
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Science. 2015 Oct 9;350(6257):207-211
pubmed: 26359337
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
Ann Oncol. 2016 Jan;27(1):147-53
pubmed: 26483045
Science. 2015 Nov 27;350(6264):1084-9
pubmed: 26541606
Science. 2015 Nov 27;350(6264):1079-84
pubmed: 26541610
Cancer Discov. 2016 Feb;6(2):202-16
pubmed: 26645196
Nat Commun. 2016 Feb 02;7:10391
pubmed: 26837003
Science. 2016 Mar 25;351(6280):1463-9
pubmed: 26940869
Lancet. 2016 May 7;387(10031):1909-20
pubmed: 26952546
Clin Cancer Res. 2016 Sep 15;22(18):4585-93
pubmed: 27225694
Ann Oncol. 2016 Oct;27(10):1953-8
pubmed: 27502709
Cell. 2016 Oct 6;167(2):397-404.e9
pubmed: 27667683
Nat Genet. 2016 Nov;48(11):1327-1329
pubmed: 27668655
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
J Gastrointest Oncol. 2016 Oct;7(5):713-720
pubmed: 27747085
J Thorac Oncol. 2017 Feb;12(2):403-407
pubmed: 27765535
Lancet. 2017 Jan 21;389(10066):255-265
pubmed: 27979383
Clin Transl Immunology. 2017 Mar 10;6(3):e133
pubmed: 28435675
CA Cancer J Clin. 2017 Jul 8;67(4):326-344
pubmed: 28481406
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
Lancet. 2017 Oct 21;390(10105):1853-1862
pubmed: 28822576
Mol Cancer Ther. 2017 Nov;16(11):2598-2608
pubmed: 28835386
Cell. 2017 Nov 2;171(4):934-949.e16
pubmed: 29033130
J Oncol. 2017;2017:5035371
pubmed: 29075294
Science. 2018 Jan 5;359(6371):97-103
pubmed: 29097493
Science. 2018 Jan 5;359(6371):91-97
pubmed: 29097494
N Engl J Med. 2017 Dec 21;377(25):2500-2501
pubmed: 29262275
JAMA Oncol. 2018 Feb 1;4(2):210-216
pubmed: 29270615
Science. 2018 Feb 16;359(6377):770-775
pubmed: 29301958
Science. 2018 Feb 16;359(6377):801-806
pubmed: 29301960
Science. 2018 Jan 5;359(6371):104-108
pubmed: 29302014
J Clin Invest. 2018 Feb 1;128(2):580-588
pubmed: 29337303
J Clin Oncol. 2018 Mar 1;36(7):633-641
pubmed: 29337640
J Immunother Cancer. 2018 Jan 23;6(1):8
pubmed: 29357948
Ann Oncol. 2018 Apr 1;29(4):1030-1036
pubmed: 29360924
Ann Oncol. 2018 Jan 1;29(1):271-279
pubmed: 29361136
Cancer J. 2018 Mar/Apr;24(2):78-83
pubmed: 29601334
Cancer Cell. 2018 May 14;33(5):843-852.e4
pubmed: 29657128
N Engl J Med. 2018 May 31;378(22):2093-2104
pubmed: 29658845
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Oncol Lett. 2018 May;15(5):6352-6360
pubmed: 29725395
Cancer Cell. 2018 May 14;33(5):853-861.e4
pubmed: 29731394
Clin Cancer Res. 2018 Nov 15;24(22):5710-5723
pubmed: 29764856
Nature. 2018 May;557(7706):575-579
pubmed: 29769722
Nat Commun. 2018 Jul 13;9(1):2724
pubmed: 30006565
Nat Med. 2018 Sep;24(9):1449-1458
pubmed: 30013197
Nat Med. 2018 Sep;24(9):1441-1448
pubmed: 30082870
Science. 2018 Oct 12;362(6411):
pubmed: 30309915
Clin Cancer Res. 2019 Apr 1;25(7):2144-2154
pubmed: 30647082
Nature. 2019 Jan;565(7741):600-605
pubmed: 30675064
Cancers (Basel). 2019 Feb 10;11(2):null
pubmed: 30744168
Nat Rev Cancer. 2019 Mar;19(3):133-150
pubmed: 30755690
Sci Rep. 2019 Feb 22;9(1):2636
pubmed: 30796310
Nat Med. 2019 Mar;25(3):454-461
pubmed: 30804515